{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:48:05Z","timestamp":1787168885571,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.3816\/clm.2002.s.005","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:01:57Z","timestamp":1221166917000},"page":"S24-S28","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Trials with Gemtuzumab Ozogamicin (Mylotarg\u00ae) Combined with Chemotherapy Regimens in Acute Myeloid Leukemia"],"prefix":"10.3816","volume":"2","author":[{"given":"Edward A.","family":"Stadtmauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.s.005_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjugate Chem"},{"key":"10.3816\/CLM.2002.s.005_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.2717946","article-title":"Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity","volume":"244","author":"Zein","year":"1989","journal-title":"Science"},{"key":"10.3816\/CLM.2002.s.005_bib3","first-page":"89","article-title":"Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model","volume":"52","author":"van der Jagt","year":"1992","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.s.005_bib4","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van Der Velden","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.005_bib5","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.s.005_bib6","first-page":"301a","article-title":"An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse","volume":"20","author":"Stadtmauer","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.s.005_bib7","series-title":"AHFS Drug Information 2000","year":"2000"},{"key":"10.3816\/CLM.2002.s.005_bib8","unstructured":"Stadtmauer EA. Gemtuzumab ozogamicin in combination with chemotherapy in AML. Paper presented at: First International Monoclonal Antibodies Meeting; August 31, 2001; Banff, Canada."},{"key":"10.3816\/CLM.2002.s.005_bib9","first-page":"587a","article-title":"Sequential administration of gemtuzumab ozagamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: interim results of the EORTC Leukemia Group AML-15A phase II trial","volume":"98","author":"Amadori","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.005_bib10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.s.005_bib11","first-page":"766a","article-title":"Gemtuzumab ozogamicin (\u201cMylotarg\u201d) in untreated acute promyelocytic leukemia","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.005_bib12","first-page":"720a","article-title":"Mylotarg +\/\u2212 IL-11 in patients age >= 65 with newly-diagnosed AML\/MDS: comparision with idarubicin + ara-C","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.005_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T16:57:52Z","timestamp":1545757072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511701543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":13,"alternative-id":["S1526965511701543"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.s.005","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}